secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001213900-25-053266
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q3 net loss narrows to $4.8M; Phase 3 data expected this month
------------------------------------------------------------------------------

- Net loss attributable to Rafael Holdings of $4.8M ($0.19 per share) vs. $32.4M loss ($1.36) in Q3 last year.
- Cash and equivalents of $37.9M at April 30, 2025; $25M rights offering closed June 4 with net proceeds of $24.9M.
- Cyclo Therapeutics merger completed March 25, 2025; TransportNPC Phase 3 trial fully enrolled for NPC1.
- 48-week interim analysis results for Trappsol Cyclo expected later this month.
- R&D expenses rose to $3.0M and G&A to $3.2M due to Cyclo consolidation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/0001213900-25-053266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/ea0245286-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-053266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer